Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Infections

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to Infectious Disease Articles

Monday, 4th April 2005

 

The results of the Mexican study strongly suggest that DOTS reduces transmission of resistant strains by curing potential multi-drug resistant cases of TB.

 
 

tellfrnd.gif (30x26 -- 1330 bytes)send to a friend
 
prntfrnd.gif (30x26 -- 1309 bytes)printer friendly version
 

 
  Related
 
  Tuberculosis info  
   
 
     

A standard and inexpensive tuberculosis treatment regimen cut the overall TB rate in half and lowered the rate of drug-resistant cases even more dramatically in a remote Mexican health district with a high prevalence of the disease. ?This shows what basic TB control can accomplish,? said Maria de Lourdes Garc? Garc?, a Howard Hughes Medical Institute international research scholar who led the Mexican study.

To learn more about TB transmission in less developed countries, Garc? Garc? and colleagues from the National Institutes of Mexico and Stanford University launched a five-year study in the Orizaba Health Jurisdiction, four hours by bus southeast of Mexico City. The district, which has a higher rate of TB than Mexico as a whole, encompasses five mostly urban communities in an industrialized valley and surrounding rural mountains.


?This shows what basic TB control can accomplish.?
Maria de Lourdes Garcia Garcia

Supported by HHMI, the U.S. National Institutes of Health, and the Wellcome Trust, the study used modern molecular epidemiologic approaches, in addition to screenings, clinical assessment of people reporting symptoms, supervised treatment, and follow-up, to explore a global health problem.

At the outset, 22 percent of previously untreated patients with pulmonary TB were carrying drug-resistant strains, and 6.7 percent had multiple-drug resistance. By the study's final year, only 7.8 percent of new TB patients carried drug-resistant strains, and there were no cases of multiple-drug resistant TB.

The researchers report their findings in the April 2, 2005 issue of the British medical journal The Lancet. A commentary by Marcos Espinal, executive secretary of the World Health Organization's Stop TB Partnership, appears in the same issue.

People with TB must take four standard drugs daily for six months. They may begin to feel better after a month, which tends to lead them to skip doses, but if they stop taking the drugs for any reason, the drugs may become ineffective and multi-drug resistant TB may result. Multi-drug resistance refers to resistance to two of the most powerful anti-TB drugs, rifampicin and isoniazid. Overcoming this drug resistance is a major goal of public health programs fighting TB.

When Garc? Garc?'s study began in 1995, regional health officials in Mexico had begun to upgrade their TB treatment program to a World Health Organization model called directly observed therapy (DOTS). The five-pronged strategy of DOTS includes political commitment to the eradication of TB, case detection by sputum microscopy, supervised administration of drugs for at least the first two months of treatment, an uninterrupted supply of all essential drugs, and a rigorous assessment of treatment and outcomes.

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


The results of the Mexican study ?strongly suggest that DOTS reduces transmission of resistant strains by curing cases of TB that otherwise could become multi-drug resistant if they are not properly treated,? said Marcos Espinal, executive secretary of the Stop TB Partnership at the World Health Organization. ?This study shows that DOTS is needed to control multi-drug resistance. Without DOTS, measures directed to multi-drug-resistant TB will not work.?

The unexpected effectiveness of DOTS in reducing the transmission of multi-drug-resistant TB in the Orizaba region of Mexico underscores the importance of a global strategy for tackling the TB pandemic, said Garc? Garc?, director of the tuberculosis unit of Mexico's National Institute of Public Health and corresponding author of The Lancet paper.

?The fact that DOTS can control drug-resistant tuberculosis is some of the best news in recent years for the field of TB control,? she added. ?It is also an urgent call for the world to do more with the cost-effective interventions already at our disposal.?

Fewer people may catch the drug-resistant form of the deadly infectious disease, but those who do are more likely to die without second-line drugs, which tend to be more expensive, Garc? Garc? and her colleagues noted. The study demonstrates the need for a new supplemental public health strategy to provide additional drugs for people with resistant strains, said Garc? Garc?.

?We need both?DOTS to cure the majority of cases, so the transmission of some drug resistant strains is stopped, and DOTS-Plus to manage patients with multiple-drug resistance, which requires special drugs " said Espinal, who wrote an accompanying editorial in the same issue of The Lancet.

The Orizaba study complied with the ethical guidelines for research in less developed countries by providing the standard of care recommended for
98 percent of the world's TB patients. Since then, a study in Peru reported better outcomes when patients with multi-drug resistant TB were given individualized, supervised therapy. ?The international research community still needs to come to an agreement about what extra care should be provided to study participants with multi-drug resistant TB,? Garc? Garc? and colleagues wrote in The Lancet paper.

Author:

Dr. Tamer Fouad, M.D.

 

 advertisement.gif (61x7 -- 0 bytes)

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.